RxDoctor Payments Data

Srinivas Prasad, MD

Cardiovascular Disease · Merritt Island, FLNPI 1699853549

Payments from drug & device makers

$1,723in general payments, 2019–2025

Across 93 payments — averaging $18.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$257
  • Novartis$228
  • Boehringer Ingelheim$151
  • Johnson & Johnson$147
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$142
  • Boston Scientific$96
  • plus $703 from 16 others

What the payments were for

  • Food & beverage$1,71099%
  • Education$141%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,723 in reported general payments places this provider in the 35th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$371,925
Medicare patients
1,313
Services billed
4,300

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban592$728,099
EntrestoSacubitril/Valsartan191$211,947
XareltoRivaroxaban129$135,361
JardianceEmpagliflozin117$130,399
Repatha SureclickEvolocumab89$76,696
FarxigaDapagliflozin Propanediol20$17,835
Metoprolol Succinate314$5,384
Diltiazem 24hr Er (Cd)Diltiazem Hcl91$5,365
Dabigatran EtexilateDabigatran Etexilate Mesylate17$4,802
Rosuvastatin Calcium305$4,258
Ranolazine ErRanolazine28$3,896
Atorvastatin Calcium353$3,505
Carvedilol266$2,576
Losartan Potassium242$2,164
ClopidogrelClopidogrel Bisulfate209$2,121

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$257$728,099592 claims
NovartisEntresto$228$211,947191 claims
Johnson & JohnsonXarelto$147$135,361129 claims
Boehringer IngelheimJardiance$151$130,399117 claims
AstraZenecaFarxiga$78$17,83520 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Merritt Island

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →